UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Self-assembled mRNA vaccines

Advanced drug delivery reviews, 2021-03, Vol.170, p.83-112

2021

Volltextzugriff (PDF)

Non-viral COVID-19 vaccine delivery systems

Advanced drug delivery reviews, 2021-02, Vol.169, p.137-151

2021

Volltextzugriff (PDF)

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

The Lancet (British edition), 2020-06, Vol.395 (10240), p.1845-1854

2020

Volltextzugriff (PDF)

A Thermostable mRNA Vaccine against COVID-19

Cell, 2020-09, Vol.182 (5), p.1271-1283.e16

2020

Volltextzugriff (PDF)

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Cancer cell, 2021-08, Vol.39 (8), p.1034-1036

2021

Volltextzugriff (PDF)

Comparison of DNA and mRNA vaccines against cancer

Drug discovery today, 2020-03, Vol.25 (3), p.552-560

2020

Volltextzugriff (PDF)

Recombinant protein vaccines, a proven approach against coronavirus pandemics

Advanced drug delivery reviews, 2021-03, Vol.170, p.71-82

2021

Volltextzugriff (PDF)

Advances in gene-based vaccine platforms to address the COVID-19 pandemic

Advanced drug delivery reviews, 2021-03, Vol.170, p.113-141

2021

Volltextzugriff (PDF)

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

The Lancet infectious diseases, 2021-04, Vol.21 (4), p.493-506

2021

Volltextzugriff (PDF)

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

Vaccine, 2016-01, Vol.34 (3), p.313-319

2016

Volltextzugriff (PDF)

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial

The Lancet (British edition), 2018-12, Vol.392 (10165), p.2718-2727

2018

Volltextzugriff (PDF)

Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study

The Lancet infectious diseases, 2021-04, Vol.21 (4), p.546-558

2021

Volltextzugriff (PDF)

NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus , is safe and immunogenic in healthy adults

Vaccine, 2012-12, Vol.30 (52), p.7594-7600

2012

Volltextzugriff (PDF)

Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across

Advanced drug delivery reviews, 2021-09, Vol.176, p.113900-113900, Article 113900

2021

Volltextzugriff (PDF)

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge

Immunity (Cambridge, Mass.), 2021-08, Vol.54 (8), p.1869-1882.e6

2021

Volltextzugriff (PDF)

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

Vaccine, 2017-03, Vol.35 (12), p.1586-1589

2017

Volltextzugriff (PDF)

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies

Cell, 2016-09, Vol.166 (6), p.1459-1470.e11

2016

Volltextzugriff (PDF)

Vaccine development for respiratory syncytial virus

Current opinion in virology, 2017-04, Vol.23, p.107-112

Graham, Barney S

2017

Volltextzugriff (PDF)

Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines

Biomedicine & pharmacotherapy, 2022-02, Vol.146, p.112527-112527, Article 112527

2022

Volltextzugriff (PDF)

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

The Lancet infectious diseases, 2017-08, Vol.17 (8), p.854-866

2017

Volltextzugriff (PDF)

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

Vaccine, 2013-01, Vol.31 (3), p.524-532

2013

Volltextzugriff (PDF)

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.351-357

2016

Volltextzugriff (PDF)

COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

European journal of cancer (1990), 2021-09, Vol.155, p.291-293

2021

Volltextzugriff (PDF)

Preclinical and clinical development of a dengue recombinant subunit vaccine

Vaccine, 2015-12, Vol.33 (50), p.7126-7134

2015

Volltextzugriff (PDF)

1 – 25 von 1.650

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.648)
Mit Volltextzugriff
(1.635)

Publikationsform

Artikel
(1.649)
Tagungsberichte
(1)

Sprache

Englisch
(1.636)
Spanisch
(10)
Französisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.521)
Life Sciences & Biomedicine
(1.518)
Animals
(1.332)
Vaccines, Synthetic - Administration & Dosage
(1.325)
Vaccines, Synthetic - Immunology
(1.249)
Immunology
(1.095)
Medicine, Research & Experimental
(947)
Research & Experimental Medicine
(947)
Biological And Medical Sciences
(827)
Female
(788)
Vaccines
(758)
Microbiology
(741)
Fundamental And Applied Biological Sciences. Psychology
(740)
Mice
(700)
Vaccines, Antisera, Therapeutical Immunoglobulins And Monoclonal Antibodies
(667)
Humans
(663)
Allergy And Immunology
(546)
Vaccines, Synthetic - Genetics
(524)
Virology
(508)
Immunization
(496)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Vaccine
(1.013)
Virology
(82)
Antiviral Research
(36)
Virus Research
(35)
Veterinary Immunology And Immunopathology
(29)
Microbes And Infection
(26)
Journal Of Virological Methods
(23)
The Lancet
(23)
Microbial Pathogenesis
(20)
The Lancet Infectious Diseases
(15)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Self-assembled mRNA vaccines

Non-viral COVID-19 vaccine delivery systems

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

A Thermostable mRNA Vaccine against COVID-19

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Comparison of DNA and mRNA vaccines against cancer

Recombinant protein vaccines, a proven approach against coronavirus pandemics

Advances in gene-based vaccine platforms to address the COVID-19 pandemic

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial

Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study

NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus , is safe and immunogenic in healthy adults

Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies

Vaccine development for respiratory syncytial virus

Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future

COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

Preclinical and clinical development of a dengue recombinant subunit vaccine

Aktive Filter

Suchergebnisse filtern